News
-
Lubiprostone Meets Primary Endpoint In Phase 3 Clinical Trial For Opioid-Induced Bowel Dysfunction (OBD)
2/3/2012
Sucampo Pharmaceuticals, Inc. (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced recently that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
-
Ampio Pharmaceuticals, Inc. Announces Statistically Significant Improvement In Pain Relief For Its Lead Product, Ampion In The Osteoarthritis Of The Knee Trial
2/1/2012
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced preliminary results of the pain score portion of the expansion phase of Ampion™ in Knee (AIK) trial which was recently completed in Australia.
-
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use In 45% Of Patients With Serious Form Of Childhood Arthritis
11/8/2011
Novartis announced recently new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001).
-
Novartis Achieves Strong Third Quarter Financial Performance And Pipeline Progress
10/28/2011
Novartis is announcing recently additional cost reduction activity, which will be executed over three to five years. Elements of the activity to include: reallocation of production within the Novartis network resulting in closure of two sites in Switzerland and one in Italy; restructuring the development organization largely in Switzerland and the US and relocating some research activities from Switzerland to the US.
-
Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
10/19/2011
Amgen (NASDAQ: AMGN) today announced the appointment of Anthony (Tony) Hooper, executive vice president, Global Commercial Operations, effective October 26th.
-
FDA Approves Remicade To Treat Ulcerative Colitis In Children 6 Years And Older
9/30/2011
The U.S. Food and Drug Administration recently approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children 6 years and older who have had inadequate response to conventional therapy.
-
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis
9/21/2011
Novartis announced recently positive results of the first pivotal Phase III trial of ACZ885 (canakinumab) in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease.
-
Trident Pharmaceuticals Announces Initiation Of Phase 1a Clinical Study Of HF1020
9/21/2011
Trident Pharmaceuticals Inc., a biotechnology company developing therapies for autoimmune diseases and allergic conditions, today announced the initiation of a Phase 1a study for HF1020, a first in class recombinant protein with immunomodulatory activity.
-
NovAliX And Galapagos Collaborate In Osteoarthritis Discovery Research Program
9/5/2011
NovAliX recently announces that it has entered into drug discovery collaboration in the field of osteoarthritis with Galapagos.
-
Lexicon To Provide Clinical Pipeline Update And Report Second Quarter 2011 Financial Results
8/8/2011
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its second quarter 2011 financial results on Monday, August 8, 2011 after the financial markets close.
This website uses cookies to ensure you get the best experience on our website. Learn more